As of November 6, 2026, Rigel Pharmaceuticals Inc. is a publicly traded company (Nasdaq: RIGL); its largest reported holder is Soleus Capital Master Fund, L.P., with 9.9% on Schedule 13G/A of August 13, 2026, then Armistice Capital (8.95%). The largest insider holding is Raul R. Rodriguez, the chief executive and president, with 273,362 shares (1.5% of shares outstanding), per Form 4 of September 3, 2026 (Schedule 13G/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Rigel Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Rigel Pharmaceuticals Inc. a real, registered company?
- Rigel Pharmaceuticals, Inc. files with the SEC under CIK 1034842 (its SEC filings).
- Its shares are listed under the ticker RIGL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RIGEL PHARMACEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Alison L. Hannah (Form 8-K filed 2026-07-01). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Rigel Pharmaceuticals Inc.'s owners and officers?
Rigel Pharmaceuticals Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 8.95% |
| Schedule 13G/A, 2026-08-13 | Soleus Capital Master Fund, L.P. | 9.9% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 6.93% |
| Schedule 13G, 2026-05-07 | Soleus Capital Master Fund, L.P. | 5.2% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 6% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 3.99% |
| Schedule 13G/A, 2025-10-07 | Morgan Stanley | 0.7% |
| Schedule 13G/A, 2025-08-14 | Armistice Capital, LLC | 8.92% |
| Schedule 13G/A, 2025-08-05 | Soleus Capital Master Fund, L.P. | 3.7% |
Questions about who owns Rigel Pharmaceuticals Inc.
Who owns Rigel Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Rigel Pharmaceuticals Inc.: Soleus Capital Master Fund, L.P. (9.9%, Schedule 13G/A, filed 2026-08-13), Armistice Capital, LLC (8.95%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (6%, Schedule 13G, filed 2026-02-09).
Who are the largest shareholders of Rigel Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Rigel Pharmaceuticals Inc. on this page are Soleus Capital Master Fund, L.P. (9.9%), Armistice Capital, LLC (8.95%) and State Street Corporation (6%).
When did Soleus Capital Master Fund, L.P. buy into Rigel Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13G/A, filed 2025-08-05, reporting 3.7%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Rigel Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rigel Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rigel Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-01 | Alison L. Hannah | departed | 2026-07-01 |
Which insiders own Rigel Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 273,362 shares (1.5% of shares outstanding) (Form 4, 2026-09-03).
- , the chief financial officer and executive vice president: 82,962 shares (0.44% of shares outstanding) (Form 4, 2026-09-03).
- , the executive vice president and chief commercial officer: 61,622 shares (0.33% of shares outstanding) (Form 4, 2026-09-03).
- , the general counsel and executive vice president: 50,559 shares (0.27% of shares outstanding) (Form 4, 2026-09-03).
- , the executive vice president and chief medical officer: 35,025 shares (0.19% of shares outstanding) (Form 4, 2026-07-10).
Shares outstanding: 18,829,972 as of 2026-11-02, from the company's latest SEC cover page.
How much has Rigel Pharmaceuticals Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-06-17).
Keep reading
More on Rigel Pharmaceuticals Inc. and the records around it.
Rigel Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/rigel-pharmaceuticals